https://www.selleckchem.com/pr....oducts/pluripotin-sc
ments only. Although it is intense in health care resources, by facilitating assessment and reconditioning, exvivo lung perfusion (EVLP) has the potential to expand the donor pool and improve lung transplant outcomes. However, inclusion criteria used in EVLP trials have not been validated. This retrospective study from 2014 to 2018 reviewed our local state-based donation organization donor records as well as subsequent recipient outcomes to explore the relation between EVLP indications used in clinical trials and recipient outcom
Curtir
Comentario
Compartilhar
